The market is poised for growth (12.88% CAGR), driven by high demand for equipment due to capacity expansions, and the adoption of single-use systems, continuous bioprocessing, and digital twinsDublin ...
Q2 2026 earnings call recap: record sales, margin expansion, raised FY26 EPS/FCF guidance, and Filtration Group deal ...
The financial trajectory of the exosome therapy market is decoupling from the broader, slower-growing regenerative medicine ...
FILSPARI drives IgAN growth, but FSGS approval could unlock a $2 billion market amid rising competition. Read here for more.